FrancophonIA/ELRC3.0 huggingface dataset:
English: The patient's medical history for hypersensitivity reactions should be carefully evaluated prior to performing the intravitreal procedure.
Croatian: Prije provođenja intravitrealnog postupka treba pažljivo provjeriti bolesnikovu anamnezu s obzirom na reakcije preosjetljivosti.
English: In both studies, subjects received either 0.3 mg or 0.5 mg ranibizumab or sham injections.
Croatian: U okviru oba ispitivanja, ispitanici su primali ili injekcije ranibizumaba u dozi od 0,3 mg ili 0,5 mg ili prividno dane injekcije.
English: There is only limited experience in the treatment of subjects with DME due to type I diabetes.
Croatian: Iskustva u liječenju osoba oboljelih od DME-a uzrokovanoga šećernom bolešću tipa
English: Figure 4 Mean change in visual acuity from baseline over time in study D2301 (RESTORE)
Croatian: Slika 4 Srednja vrijednost promjene vidne oštrine od početne vrijednosti tijekom vremena ispitivanja D2301 (RESTORE)
English: Lucentis 10 mg/ml solution for injection
Croatian: Lucentis 10 mg/ml otopina za injekciju
English: Each vial contains 2.3 mg ranibizumab in 0.23 ml solution.
Croatian: Svaka bočica sadrži 2,3 mg ranibizumaba u 0,23 ml otopine.
English: Statistically significant patient-reported visual functioning benefits were observed in both MARINA and ANCHOR with ranibizumab treatment over the control group as measured by the NEI VFQ-25.
Croatian: Statistički značajne koristi za vidnu funkciju prema navodima bolesnika bile su uočene u oba ispitivanja, MARINA i ANCHOR, uz liječenje ranibizumabom u odnosu na kontrolnu skupinu, mjereno pomoću upitnika NEI VFQ-25.
English: Binding of VEGF-A to its receptors leads to endothelial cell proliferation and neovascularisation, as well as vascular leakage, all of which are thought to contribute to the progression of the neovascular form of age-related macular degeneration, pathologic myopia and CNV or to visual impairment caused by either diabetic macular oedema or macular oedema secondary to RVO.
Croatian: Vezanjem VEGF-A na njegove receptore dolazi do proliferacije endotelnih stanica i neovaskularizacije, te se povećava vaskularna propusnost, a smatra se da to sve doprinosi razvoju neovaskularnog oblika senilne makularne degeneracije, patološke miopije i CNV-a ili nastanku poremećaja vida uzrokovanog bilo dijabetičkim makularnim edemom, bilo makularnim edemom posljedičnim RVO-u.
English: To prepare Lucentis for intravitreal administration to preterm infants, please adhere to the instructions for use included in the VISISURE kit.
Croatian: Kako biste pripremili Lucentis za intravitrealnu primjenu u prijevremeno rođene dojenčadi, molimo da se pridržavate uputa za uporabu koje su uključene u komplet VISISURE.
English: Aseptically and firmly assemble an injection needle (30G x ½″, 0.3 mm x 13 mm) onto the syringe.
Croatian: Iglu za injekciju (30G x ½″, 0,3 mm x 13 mm) treba aseptički i čvrsto spojiti na štrcaljku.
English: Mean change in BCVA at Month 24
Croatian: (slova) (SD) Srednja promjena u BCVA-u u 24. mjesecub
English: - Do not use this medicine after the expiry date which is stated on the carton and pre-filled syringe label after EXP.
Croatian: - Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i naljepnici napunjene štrcaljke iza oznake „Rok valjanosti“, odnosno „EXP“.
English: Allergic reactions (rash, urticaria, pruritus, erythema)
Croatian: Alergijske reakcije (osip, urtikarija, svrbež, eritem) Poremećaji mišićno-koštanog sustava i vezivnog tkiva Vrlo često
English: • a subretinal haemorrhage involving the centre of the fovea, or, if the size of the haemorrhage is
Croatian: • subretinalnog krvarenja koje zahvaća središte fovee, ili krvarenja koje zahvaća ≥50%, ukupne površine lezije;
English: • ranibizumab 0.5 mg monotherapy on a TE regimen,
Croatian: • ranibizumaba 0,5 mg kao monoterapije po LIP režimu,
English: The most frequently reported side effects are described below:
Croatian: Najučestalije prijavljene nuspojave opisane su u nastavku:
English: Set dose to 0.05 ml dose mark.
Croatian: Podesite dozu na oznaku doze od 0,05 ml.
English: Patients gaining ≥15 letters from baseline or reaching 84 letters at Month 2
Croatian: Bolesnici s povećanjem od ≥15 slova u odnosu na početnu vrijednost ili koji su dosegli 84 slova nakon 2 mjeseca
English: Blindness, endophthalmitis, hypopyon, hyphaema, keratopathy, iris adhesion, corneal deposits, corneal oedema, corneal striae, injection site pain, injection site irritation, abnormal sensation in eye, eyelid irritation.
Croatian: Sljepoća, endoftalmitis, hipopion, hifema, keratopatija, adhezija šarenice, depoziti rožnice, edem rožnice, strije rožnice, bol na mjestu injekcije, iritacija na mjestu injekcije, neuobičajen osjet u oku, nadražaj očnog kapka.
English: Mean average BCVA change from Month 1 to Month 12 compared to baseline (letters)
Croatian: Srednja prosječna promjena BCVA od 1. do 12. mjeseca u usporedbi s početnom vrijednošću (slova)
English: Categorised change from baseline
Croatian: Kategorizirana promjena u odnosu na početno stanje
English: To prepare Lucentis for intravitreal administration to adults, please adhere to the following instructions:
Croatian: Kako biste pripremili Lucentis za intravitrealnu primjenu odraslima, molimo da se pridržavate sljedećih uputa:
English: Non-visual side effects include: Sore throat, nasal congestion, runny nose, headache and joint pain.
Croatian: Nuspojave koje nisu povezane s vidom uključuju: grlobolju, začepljenje nosa, curenje iz nosa, glavobolju i bol u zglobovima.
English: Mean change in BCVA at Month 12 (SD)
Croatian: Srednja promjena BCVA u 12. mjesecu (SD)
English: The injection volume of 0.02 ml is then delivered.
Croatian: Zatim se injicira volumen injekcije od 0,02 ml.
English: Proper aseptic injection techniques must always be used when administering Lucentis.
Croatian: Pri primjeni Lucentisa treba se uvijek služiti odgovarajućom tehnikom aseptične primjene injekcije.
English: Following intravitreal administration of Lucentis to preterm infants with ROP at a dose of 0.2 mg (per eye), serum ranibizumab concentrations were higher than those observed in neovascular AMD adult patients receiving 0.5 mg in one eye. Based on a population pharmacokinetic analysis, the differences in Cmax and AUCinf were approximately 16-fold and 12-fold higher, respectively.
Croatian: Nakon intravitrealne primjene Lucentisa prijevremeno rođenoj dojenčadi s ROP-om u dozi od 0,2 mg (po oku), koncentracije ranibizumaba u serumu bile su više od onih opaženih u odraslih bolesnika s neovaskularnim AMD-om koji su primili 0,5 mg u jedno oko.
English: All injections will be administered by your eye doctor.
Croatian: Svaku injekciju će Vam dati Vaš liječnik za liječenje bolesti oka.
English: Ocular adverse reactions reported in more than one patient treated with ranibizumab 0.2 mg were retinal haemorrhage and conjunctival haemorrhage.
Croatian: Okularne nuspojave prijavljene u više od jednog bolesnika liječenog ranibizumabom 0,2 mg bile su krvarenje mrežnice i krvarenje konjunktive.
English: It contains the active substance called ranibizumab.
Croatian: Sadrži djelatnu tvar koja se naziva ranibizumab.
English: Outcome measures at Month 12 compared to baseline in study D2301 (RESTORE)
Croatian: Mjere ishoda u 12. mjesecu u usporedbi s početnim vrijednostima u ispitivanju D2301 (RESTORE)
English: Sham (n=238)
Croatian: Placebo postupak (n=238)
English: The sterility of the pre-filled syringe cannot be guaranteed unless the tray remains sealed.
Croatian: Sterilnost napunjene štrcaljke ne može se jamčiti ako kaseta nije zatvorena.
English: Dispose of the syringe cap (see Figure 3).
Croatian: 6. Odložite zatvarač štrcaljke (vidjeti Sliku 3).
English: The most serious side effects are described below:
Croatian: Najozbiljnije nuspojave opisane su u nastavku:
English: lesion as assessed by optical coherence tomography and/or fluorescence angiography).
Croatian: definiranim kao oštećenje vida koje se može pripisati intra- ili subretinalnoj tekućini ili aktivnom propuštanju uzrokovanom CNV lezijom procijenjeno optičkom koherentnom tomografijom i/ili fluoresceinskom angiografijom).
English: To prepare Lucentis for intravitreal administration to preterm infants please adhere to the instructions for use in the VISISURE kit.
Croatian: Kako biste pripremili Lucentis za intravitrealnu primjenu u prijevremeno rođene dojenčadi, molimo da se pridržavate uputa za uporabu u kompletu VISISURE.
English: Very common side effects (may affect more than 1 in 10 people) Visual side effects include: Inflammation of the eye, visual disturbances, eye pain, small particles or spots in your vision (floaters), eye irritation, a feeling of having something in the eye, increased tear production, inflammation or infection of the eyelid margins, dry eye, redness or itching of the eye and increased eye pressure.
Croatian: Vrlo česte nuspojave (mogu se javiti u više od 1 na 10 osoba) Nuspojave povezane s vidom uključuju: upalu oka, poremećaje vida, bol u oku, sitne čestice ili mrlje u Vašem vidnom polju (plutajuće mutnine), nadražaj oka, osjećaj da Vam je nešto u oku, pojačano suzenje, upalu ili infekciju rubova očnih kapaka, suho oko, crvenilo ili svrbež oka i povišeni očni tlak.
English: • ranibizumab 0.5 mg monotherapy on a PRN regimen.
Croatian: • ranibizumaba 0,5 mg kao monoterapije po režimu p.p..
English: Non-visual side effects include: Urinary tract infection, low red blood cells count (with symptoms such as tiredness, breathlessness, dizziness, pale skin), anxiety, cough, nausea, allergic reactions like rash, hives, itching and skin reddening.
Croatian: Nuspojave koje nisu povezane s vidom uključuju: infekciju mokraćnog sustava, nisku razinu eritrocita (sa simptomima kao što su umor, nedostatak zraka, omaglica, bljedoća kože), tjeskobu, kašalj, mučninu, alergijske reakcije kao što su osip, koprivnjača, svrbež i crvenilo kože.
English: Single-use pre-filled syringe for intravitreal use only.
Croatian: Napunjena štrcaljka za jednokratnu uporabu isključivo za intravitrealnu primjenu.
English: Statistically significant patient-reported benefits in subscales related to near and distance activity were observed with ranibizumab treatment over the control group as measured by the NEI VFQ-25.
Croatian: Statististički značajne koristi prema navodima bolesnika u podljestvicama povezanima s vidom na blizinu i na daljinu bile su uočene uz liječenje ranibizumabom u odnosu na kontrolnu skupinu, mjereno upitnikom NEI VFQ-25.
English: • Group I (ranibizumab 0.5 mg, dosing regimen driven by “stability” criteria defined as no change in BCVA compared to two preceding monthly evaluations).
Croatian: • I. skupina (ranibizumab 0,5 mg, režim doziranja utvrđen prema kriterijima „stabilnosti“
English: Vial containing 2.3 mg of ranibizumab.
Croatian: Bočica sadrži 2,3 mg ranibizumaba.
English: Assemble a 5 µm filter needle (18G x 1½″, 1.2 mm x 40 mm, 5 µm) onto a 1 ml syringe using aseptic technique.
Croatian: Na štrcaljku od 1 ml stavite iglu s filterom promjera pora 5 µm (18G x 1½″, 1,2 mm x 40 mm, 5 µm) koristeći aseptičku tehniku.
English: Outcome measure at Month 36 compared to D2301 (RESTORE) baseline in study D2301-E1 (RESTORE Extension)
Croatian: Mjera ishoda u 36. mjesecu u ispitivanju D2301-E1 (RESTORE Produžetak) u usporedbi s početnom vrijednošću u ispitivanju D2301 (RESTORE)
English: PRN ranibizumab 0.5 mg n=117
Croatian: p.p. ranibizumab 0.5 mg n=117
English: Withholding Lucentis
Croatian: Nedavanje Lucentisa
English: If you have any further questions on the use of this medicine, ask your baby's doctor.
Croatian: U slučaju bilo kakvih pitanja u vezi s primjenom ovog lijeka, obratite se djetetovom liječniku.
English: Non-visual side effects include: Sore throat, nasal congestion and runny nose, low red blood cell counts (with symptoms such as tiredness, breathlessness, pale skin), cough, urinary tract infection, allergic reactions like rash and skin reddening.
Croatian: Nuspojave koje nisu povezane s vidom uključuju: grlobolju, začepljenje nosa i curenje iz nosa, nisku razinu eritrocita (sa simptomima kao što su umor, nedostatak zraka, blijeda koža), kašalj, infekciju mokraćnog sustava, alergijske reakcije kao što su osip i crvenilo kože.
English: This provides a suitable amount to deliver a single dose of 0.02 ml containing 0.2 mg ranibizumab.
Croatian: Time se dobiva iskoristiva količina za primjenu jedne doze od 0,02 ml koja sadrži 0,2 mg ranibizumaba.
English: • Group II (ranibizumab 0.5 mg, dosing regimen driven by “disease activity” criteria defined as vision impairment attributable to intra- or subretinal fluid or active leakage due to the CNV
Croatian: • II. skupina (ranibizumab 0,5 mg, režim doziranja utvrđen prema kriterijima „aktivnosti bolesti“
English: Vitritis, vitreous detachment, retinal haemorrhage, visual disturbance, eye pain, vitreous floaters, conjunctival haemorrhage, eye irritation, foreign body sensation in eyes, lacrimation increased, blepharitis, dry eye, ocular hyperaemia, eye pruritus.
Croatian: Vitritis, ablacija staklovine, krvarenje mrežnice, poremećaj vida, bol u oku, plutajući opaciteti u staklovini, krvarenje konjunktive, iritacija oka, osjećaj stranog tijela u očima, pojačano suzenje, blefaritis, suho oko, hiperemija oka, svrbež oka.
English: Very common side effects (may affect more than 1 in 10 people) Visual side effects include: Inflammation of the eye, bleeding in the back of the eye (retinal bleeding), visual disturbances, eye pain, small particles or spots in your vision (floaters), bloodshot eye, eye irritation, a feeling of having something in the eye, increased tear production, inflammation or infection of the eyelid margins, dry eye, redness or itching of the eye and increased eye pressure.
Croatian: Vrlo česte nuspojave (mogu se javiti u više od 1 na 10 osoba) Nuspojave povezane s vidom uključuju: upalu oka, krvarenje u stražnjem dijelu oka (krvarenje mrežnice), poremećaje vida, bol u oku, sitne čestice ili mrlje u Vašem vidnom polju (plutajuće mutnine), krvni podljev oka, nadražaj oka, osjećaj da Vam je nešto u oku, pojačano suzenje, upalu ili infekciju rubova očnih kapaka, suho oko, crvenilo ili svrbež oka i povišeni očni tlak.
English: Prior ranibizumab 0.5 mg + laser n=83
Croatian: Prethodni ranibizumab 0,5 mg + laser n=83
English: Note: Grip at the hub of the injection needle while removing the cap.
Croatian: Napomena: Čvrsto držite bazu igle za injekciju prilikom skidanja zatvarača.
English: If you observe any side effects in your baby, talk to your baby`s doctor.
Croatian: Ako primijetite bilo koju nuspojavu kod svog djeteta, potrebno je obavijestiti djetetovog liječnika.
English: ≥3-step improvement n (%)
Croatian: Poboljšanje za ≥3 koraka n (%)
English: The recommended dose for Lucentis is 0.5 mg given as a single intravitreal injection.
Croatian: Preporučena doza Lucentisa iznosi 0,5 mg u obliku jednokratne intravitrealne injekcije.
English: For preparation and intravitreal injection the following medical devices for single use are needed: - a 5 µm filter needle (18G); not included within the Lucentis pack - a low volume high accuracy sterile syringe (supplied separately inside the VISISURE kit) - an injection needle (30G x ½″); (supplied separately inside the VISISURE kit)
Croatian: Za pripremu i intravitrealnu injekciju potrebni su sljedeći medicinski proizvodi za jednokratnu uporabu: - igla s filterom promjera pora od 5 µm (18G); nije uključena u pakiranje Lucentisa - precizna sterilna štrcaljka malog volumena (isporučuje se zasebno u kompletu VISISURE) - igla za injekciju (30G x ½″); (isporučuje se zasebno u kompletu VISISURE)
English: Systemic adverse events including non-ocular haemorrhages and arterial thromboembolic events have been reported following intravitreal injection of VEGF inhibitors.
Croatian: Nakon intravitrealne injekcije VEGF inhibitora zabilježeni su sistemski štetni događaji koji uključuju krvarenja koja nisu povezana s okom te arterijske tromboembolijske događaje.
English: 7.3 (sham)
Croatian: 6,1 (5,7) a
English: The recommended dose for Lucentis in preterm infants is 0.2 mg given as an intravitreal injection.
Croatian: Preporučena doza Lucentisa u prijevremeno rođene dojenčadi iznosi 0,2 mg u obliku intravitrealne injekcije.
English: 95% CI Comparison Odds ratio (OR)
Croatian: Usporedba Omjer izgleda (OR)
English: The most frequently reported ocular adverse reactions following injection of Lucentis are: eye pain, ocular hyperaemia, increased intraocular pressure, vitritis, vitreous detachment, retinal haemorrhage, visual disturbance, vitreous floaters, conjunctival haemorrhage, eye irritation, foreign body sensation in eyes, increased lacrimation, blepharitis, dry eye and eye pruritus.
Croatian: Lucentisa su: bol u oku, hiperemija oka, povišeni intraokularni tlak, vitritis, ablacija staklovine, krvarenje mrežnice, poremećaj vida, plutajući opaciteti u staklovini, krvarenje konjunktive, iritacija oka, osjećaj stranog tijela u oku, pojačano suzenje, blefaritis, suho oko i svrbež oka.
English: TE ranibizumab 0.5 mg alone n=125
Croatian: LIP samo ranibizumab 0,5 mg n=125
English: Elderly (age 65 years and over)
Croatian: Djeca i adolescenti (mlađi od 18 godina starosti)
English: Visual side effects include: Decreased sharpness of vision, swelling of a section of the eye (uvea, cornea), inflammation of the cornea (front part of eye), small marks on the surface of the eye, blurred vision, bleeding at the site of injection, bleeding in the eye, discharge from the eye with itching, redness and swelling (conjunctivitis), light sensitivity, eye discomfort, swelling of the eyelid, eyelid pain.
Croatian: Nuspojave povezane s vidom uključuju: smanjenje oštrine vida, oticanje dijelova oka (srednji sloj oka, rožnica), upalu rožnice (prednjeg dijela oka), mali znakovi na površini oka, zamućeni vid, krvarenje na mjestu primjene injekcije, krvarenje u oku, iscjedak iz oka uz svrbež, crvenilo i oticanje (konjunktivitis), osjetljivost na svjetlost, osjećaj neugode u oku, oticanje kapka, bol u kapku.
English: The recommended dose for Lucentis in adults is 0.5 mg given as a single intravitreal injection.
Croatian: Preporučena doza Lucentisa u odraslih iznosi 0,5 mg u obliku jednokratne intravitrealne injekcije.
English: This provides a usable amount to deliver a single dose of 0.05 ml containing 0.5 mg ranibizumab.
Croatian: To osigurava upotrebljivu količinu za isporuku jednokratne doze od 0,05 ml koja sadrži 0,5 mg ranibizumaba.
English: Pack size of one pre-filled syringe.
Croatian: Veličina pakiranja je jedna napunjena štrcaljka.
English: Rubber stopper
Croatian: Gumeni čep
English: Keep the pre-filled syringe in its sealed tray in the carton to protect from light.
Croatian: Napunjenu štrcaljku držite u zatvorenoj kaseti u kutiji radi zaštite od svjetlosti.
English: (letters) (SD) (primary endpoint) Mean change in BCVA at Month 12 (letters) (SD) Gain of ≥15 letters in visual acuity at Month 6
Croatian: (slova) (SD) (primarna mjera ishoda) Srednja promjena BCVA nakon 12 mjeseci liječenja (slova) (SD)
English: Visual side effects include: Decreased sharpness of vision, swelling of a section of the eye (uvea, cornea), inflammation of the cornea (front part of eye), small marks on the surface of the eye, blurred vision, discharge from the eye with itching, redness and swelling (conjunctivitis), light sensitivity, eye discomfort, swelling of the eyelid, eyelid pain.
Croatian: Nuspojave povezane s vidom uključuju: smanjenje oštrine vida, oticanje dijelova oka (srednji sloj oka, rožnica), upalu rožnice (prednjeg dijela oka), mali znakovi na površini oka, zamućeni vid, iscjedak iz oka uz svrbež, crvenilo i oticanje (konjunktivitis), osjetljivost na svjetlost, osjećaj neugode u oku, oticanje kapka, bol u kapku.
English: Lucentis and laser photocoagulation in DME and in macular oedema secondary to BRVO There is some experience of Lucentis administered concomitantly with laser photocoagulation (see section 5.1).
Croatian: Postoje izvjesna iskustva vezana uz istodobno provođenje terapije Lucentisom i laserske fotokoagulacije (vidjeti dio 5.1).
English: Figure 3 Mean change from baseline BCVA over time to Month 12 (MINERVA)
Croatian: CSFT - centralna retinalna debljina Slika 3 Srednja vrijednost promjene u odnosu na početni BCVA tijekom vremena do 12. mjeseca (MINERVA)
English: Lucentis 10 mg/ml solution for injection in pre-filled syringe
Croatian: Lucentis 10 mg/ml otopina za injekciju u napunjenoj štrcaljki
English: Patients not losing >15 letters from baseline at Month 2
Croatian: Bolesnici bez smanjenja za >15 slova u odnosu na početnu vrijednost nakon 2 mjeseca Smanjenje CSFT-a b od početne vrijednosti do
English: For preparation and intravitreal injection the following medical devices for single use are needed: - a 5 µm filter needle (18G) - a 1 ml sterile syringe (including a 0.05 ml mark) - an injection needle (30G x ½″).
Croatian: Za pripremu i intravitrealnu injekciju potrebni su sljedeći medicinski proizvodi za jednokratnu uporabu: - igla s filterom promjera pora od 5 µm (18G) - sterilna štrcaljka od 1 ml (sadrži 0,05 ml oznaku) - igla za injekciju (30G x ½″).
English: Sham (n=59)
Croatian: Placebo postupak (n=59)
English: For preparation and intravitreal injection the following medical devices for single use are needed: - a 5 µm filter needle (18G x 1½″, 1.2 mm x 40 mm, provided) - a 1 ml sterile syringe (including a 0.05 ml mark, not included within the Lucentis pack) - an injection needle (30G x ½″; not included within the Lucentis pack)
Croatian: Za pripremu i intravitrealnu injekciju potrebni su sljedeći medicinski proizvodi za jednokratnu uporabu: - igla s filterom promjera pora od 5 µm (18G x 1½″, 1,2 mm x 40 mm, priložena) - sterilna štrcaljka od 1 ml (sadrži 0,05 ml oznaku, nije uključena u pakiranje Lucentisa) - igla za injekciju (30G x ½″; nije uključena u pakiranje Lucentisa)
English: - If you have an infection in or around your eye. - If you have pain or redness (severe intraocular inflammation) in your eye.
Croatian: - Ako imate infekciju u ili oko oka.
English: In adults the injection needle should be inserted 3.5-4.0 mm posterior to the limbus into the vitreous cavity, avoiding the horizontal meridian and aiming towards the centre of the globe.
Croatian: U odraslih iglu za injekciju treba uvesti 3,5-4,0 mm posteriorno od limbusa u vitrealnu šupljinu,u smjeru središta očne jabučice, pri čemu treba izbjegavati horizontalni meridijan.
English: Lucentis 10 mg/ml solution for injection ranibizumab
Croatian: Lucentis 10 mg/ml otopina za injekciju ranibizumab
English: Single dose for adults: 0.5 mg/0.05 ml.
Croatian: Jednokratna doza za odrasle: 0,5 mg/0,05 ml. Suvišak volumena treba izbaciti.
English: Children and adolescents (below 18 years of age) Except for retinopathy of prematurity, the use of Lucentis in children and adolescents has not been established and is therefore not recommended.
Croatian: Osim za retinopatiju nedonoščadi, primjena Lucentisa u djece i adolescenata nije ustanovljena te se stoga ne preporučuje.
English: Lucentis and laser photocoagulation in DME and macular oedema secondary to BRVO There is some experience of Lucentis administered concomitantly with laser photocoagulation.
Croatian: Lucentis i laserska fotokoagulacija kod DME-a i makularnog edema posljedičnog BRVO-u
English: Inject slowly until the rubber stopper reaches the bottom of the syringe to deliver the volume of 0.05 ml.
Croatian: 13. Zatim polagano injicirajte volumen injekcije od 0,05 ml sve dok gumeni čep ne dotakne dno štrcaljke.
English: ≥3-step worsening n (%)
Croatian: Pogoršanje za ≥3 koraka n (%)
English: For preparation and intravitreal injection the following medical devices for single use are needed: - a 5 µm filter needle (18G x 1½″, 1.2 mm x 40 mm, provided) - a low volume high accuracy sterile syringe (supplied separately inside the VISISURE kit) - an injection needle (30G x ½″) (supplied separately inside the VISISURE kit)
Croatian: Za pripremu i intravitrealnu injekciju potrebni su sljedeći medicinski proizvodi za jednokratnu uporabu: - igla s filterom promjera pora od 5 µm (18G x 1½″, 1,2 mm x 40 mm, priložena) - precizna sterilna štrcaljka malog volumena (isporučuje se zasebno u kompletu VISISURE) - igla za injekciju (30G x ½″) (isporučuje se zasebno u kompletu VISISURE)